CN113481139B - Recombinant bacillus subtilis for producing glycocyamine and construction method thereof - Google Patents
Recombinant bacillus subtilis for producing glycocyamine and construction method thereof Download PDFInfo
- Publication number
- CN113481139B CN113481139B CN202110867868.1A CN202110867868A CN113481139B CN 113481139 B CN113481139 B CN 113481139B CN 202110867868 A CN202110867868 A CN 202110867868A CN 113481139 B CN113481139 B CN 113481139B
- Authority
- CN
- China
- Prior art keywords
- bacillus subtilis
- glycocyamine
- recombinant bacillus
- recombinant
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/04—Amidinotransferases (2.1.4)
- C12Y201/04001—Glycine amidinotransferase (2.1.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses recombinant bacillus subtilis for producing glycocyamine and a construction method thereof, belonging to the technical field of bacillus subtilis metabolic engineering and genetic engineering. The recombinant Bacillus subtilis obtained by the invention is prepared by taking wild Bacillus subtilis as an initial strain and introducing exogenous arginine on a Bacillus subtilis genome: the yield of the recombinant strain with high yield of the glycocyamine obtained by glycine amidine transferase reaches 12.8g/L, and the synthesis of the glycocyamine in bacillus subtilis is realized for the first time. The method lays a foundation for the efficient production of glycocyamine in the bacillus subtilis metabolic engineering.
Description
Technical Field
The invention relates to recombinant bacillus subtilis for producing glycocyamine and a construction method thereof, belonging to the technical field of bacillus subtilis metabolic engineering and genetic engineering.
Background
Guanidinoacetic acid (GAA), also known as guanidinoacetic acid, is a naturally occurring amino acid derivative. Guanidinoacetic acid is currently widely used in animal production as a feed additive to increase muscle production. At present, the synthesis of guanidine compounds is mainly performed by chemical synthesis, and most chemical processes have the problems of complex routes and environmental unfriendliness, so that the research and development of a guanidine drug synthesis process which is synthesized by a microbial synthesis method and has no pollution to the environment and is economic has important significance.
Bacillus subtilis has wide industrial application and plays an important role in producing protein and high value-added compounds. At the same time, it is a non-pathogenic microorganism that has been recognized by the U.S. Food and Drug Administration (FDA) as a safe (GRAS) food grade microorganism. In addition, bacillus subtilis has a number of advantages, including: the growth rate of the cells is high, the fermentation culture time is short, the culture condition requirement is low, the metabolic engineering modification is easy to carry out, the protein secretion capacity is strong, and the like.
The expression intensity of the genetic element is changed to achieve the purpose of optimizing metabolic pathways, and further realize the high-efficiency synthesis of target products. The regulation of the expression strength of key genes through promoters is a common and important regulation strategy for controlling the flow of carbon flux to a target product synthesis pathway. At present, GAA is produced by expression in Escherichia coli, which belongs to pathogenic strains, can produce endotoxin and is not suitable for serving as a food additive or a feed additive. Bacillus subtilis is more suitable for GAA production than Escherichia coli, but because it does not contain a GAA-producing pathway by itself, it poses a certain difficulty in GAA production using Bacillus subtilis.
Disclosure of Invention
The invention aims to solve the technical problem of providing a recombinant bacillus subtilis strain for producing glycocyamine and a construction method thereof. Promoters with different strengths capable of increasing or reducing protein expression are used for starting the heterologous glycine amidine transferase AGAT, the key gene AGAT in the GAA biosynthetic pathway is inserted into the original nucleotide sequence to realize the up-regulation or down-regulation of the expression quantity of the target gene, and finally, the change of intracellular metabolic flow is realized to improve the yield of the GAA.
The invention provides a recombinant bacillus subtilis which expresses glycine amidine transferase AGAT derived from Amycolatopsis kentuckyensis and knockouts gcvP and/or argI genes in a genome.
In one embodiment, the argI gene is the first gene in the arginolytic pathway and the first gene in the glycinolytic pathway gcvP.
In one embodiment, the nucleotide sequence of the gene encoding the glycine amidinyltransferase AGAT is as shown in SEQ ID No. 12.
In one embodiment, the glycine amidinase AGAT is expressed using promoters of different strengths; the promoters of different strengths comprise P xpac 、P ycec 、P lytR 、P sdhB 、P 43 、P odhA 、P 333 、P yvyD 、P veg Or P 566 。
In one embodiment, the promoter P xpac 、P ycec 、P lytR 、P sdhB 、P 43 、P odhA 、P 333 、P yvyD 、P veg 、 P 566 The nucleotide sequences of (A) are respectively shown in SEQ ID NO. 1-10.
In one embodiment, the GeneID of the gcvP gene is 938549; the GeneID of the argI gene is 937760.
In one embodiment, the pHT01 plasmid is used as an expression vector.
In one embodiment, bacillus subtilis168 is used as a starting strain.
The invention provides a method for producing glycocyamine, which takes recombinant bacillus subtilis as a fermentation strain and glycine and arginine as substrates to produce glycocyamine through fermentation.
In one embodiment, the concentration of glycine and arginine in the reaction system is the same and is 15 to 25g/L.
In one embodiment, the glycine and arginine are present in the reaction system at a concentration of 20g/L each.
In one embodiment, the OD of the recombinant Bacillus subtilis in the reaction system 600 60 + -2, and reacting at pH 7.5.
In one embodiment, the reaction system contains 35-45 g/L glucose, 10-15 g/L yeast powder, 5-10 g/L tryptone, 5-10 g/L ammonium sulfate, 10-15 g/L dipotassium hydrogen phosphate trihydrate, 2-5 g/L potassium dihydrogen phosphate, 1-5 g/L magnesium chloride and 5-10 g/L urea.
In one embodiment, the reaction system contains 40g/L glucose, 12g/L yeast powder, 6g/L tryptone, 6g/L ammonium sulfate, 12g/L dipotassium hydrogen phosphate trihydrate, 2.5g/L potassium dihydrogen phosphate, 3g/L magnesium chloride and 6g/L urea.
In one embodiment, the reaction is carried out at 25 to 40 ℃ for 24 to 48 hours.
In one embodiment, the reaction is carried out at 30 ℃ for 48h.
The invention provides application of bacillus subtilis in production of glycocyamine.
The invention has the beneficial effects that: the bacillus subtilis belongs to a food safety level microorganism, and the produced GAA meets the food safety requirement and can be directly used as a food additive or a feed additive. According to the invention, the metabolic pathway of GAA production is modified in Bacillus subtilis168, the obtained strain is used for producing GAA through whole-cell transformation, the reaction lasts for 48h, and the final yield can reach 12.8g/L.
Detailed Description
Culturing and fermenting recombinant bacillus subtilis seeds:
seed liquid culture medium: 10g/L tryptone, 10g/L sodium chloride and 5g/L yeast powder.
The formula of the fermentation medium is as follows: 40g/L glucose, 12g/L yeast powder, 6g/L tryptone, 6g/L ammonium sulfate, 12g/L dipotassium hydrogen phosphate trihydrate, 2.5g/L potassium dihydrogen phosphate, 3g/L magnesium chloride and 6g/L urea.
Whole cell transformation process: first, single colonies were picked up into 3mL of seed culture medium and cultured at 37 ℃ for 10 hours at 220 rpm. Then, 2.5mL of the seed solution was transferred to 50mL of fermentation medium, and the corresponding antibiotic was added at 37 ℃ and 220rpm for 20 hours, and a small amount of the bacterial solution was diluted to an appropriate multiple (about 50 times) to measure OD 600 About 30 ℃ or so, the fermentation broth was centrifuged at 4 ℃ and 4000rpm for 10min to collect cell pellets, which were then washed once with a predetermined volume of 0.01M PBS buffer, pH 7.5. All cells were added to 25mL of a mixture containing 20g/L arginine and 20g/L glycineAnd one-ten-thousand chloromycetin in the catalytic reaction system, and then OD in the system 600 60. + -.2, the catalytic reaction was carried out in 0.01M PBS buffer, pH 7.5. Adding 5mL of the reaction system into a 50mL centrifuge tube in a reaction container, carrying out whole cell transformation reaction in a constant temperature shaking table at 30 ℃ and 220rpm/min, and collecting the concentration change of a sample detection product respectively for transformation of 4h,10h,24h and 48h.
The sample detection method comprises the following steps: detection of guanidinoacetic acid Agilent high performance liquid chromatography (equipped with UV absorber) was used with a Waters Xbridge BEH Amide 3.5 μm column (4.6 mm. Times.150 mm). The mobile phase was 75% acetonitrile (analytical grade) (ammonia adjusted to pH 10), the detection wavelength was 210nm, and the flow rate was 1mL/min. Adding 600 mul of 50% acetonitrile (analytically pure) into each 300 mul of sample after whole cell transformation, diluting the sample by 3 times, evenly mixing, centrifuging at 14000rpm/min for 10min, and taking 600 mul of supernatant for detection.
EXAMPLE 1 construction of plasmid pHT01-agat
Synthesizing a nucleotide sequence (shown as SEQ ID NO. 12) of an AGAT gene according to glycine amidino transferase AGAT (shown as an amino acid sequence in SEQ ID NO. 11) from Amycolatopsis kentuckyensis, designing a primer, respectively connecting sequences with the nucleotide sequences shown as SEQ ID NO. 1-10 and the SEQ ID NO.12 to obtain recombinant fragments, respectively connecting the recombinant fragments to pHT01 plasmid in a Gibson assembly mode, and constructing to obtain recombinant plasmids containing different promoter expression AGATs.
With the promoter P 333 Primers fx-PS7333-F and fx-PS7333-R were designed for the examples,
fx-PS7333-F：
5’-
tcctacaattcttgatataatattctcatagtttgaaaaaggaggtgataaaaATGAGAACAGATACAAGAATTGTTAATT CATGGAATG-3’，
fx-PS7333-R：
5’-aatattatatcaagaattgtaggattaagcaactgaaatttttaagtcaaaattctatgattcctcaagagctcgaattcactggccgtc- 3’；
with the promoter P 566 Primers fx-p10-F and fx-p10-R were designed for the examples,
fx-p10-F：
5’-
tcttttgagaatatgttatattatcagaaaggaggtgataaaaATGAGAACAGATACAAGAATTGTTAATTCATGG AATG-3’，
fx-p10-R：
5’-gataatataacatattctcaaaagagtgtcaaccctctatttcgagaggccgttttttgagctcgaattcactggccgtc-3’。
TABLE 1 respective promoter sequences
Example 2 construction of recombinant Bacillus subtilis containing pHT01 plasmids of different AGAT expression intensities
The plasmids constructed in example 1 were transformed into Bacillus subtilis168, respectively, and plated on plates at 37 ℃ until single colonies grew.
And (3) selecting a single colony, verifying by using primers yz-PHT01-F and yz-PHT01-R to obtain a 1.7kb band, and verifying that the recombinant bacillus subtilis is successfully constructed.
yz-PHT01-F：5’-gataataagggtaactattgccgatcgtccattc-3’，
yz-PHT01-R：5’-gtacagggactattcctaataagccgatattagcc-3’。
Example 3 ligation of reporter Gene GFP after AGAT to characterize the amount of enzyme expressed
In order to measure the expression level of AGAT, a reporter gene GFP was ligated behind the AGAT gene to construct a fusion protein AGAT-GFP, which was ligated to pHT01 plasmid, and the promoters were the ten promoters with different strengths as described above. The sequence with the nucleotide sequence shown as SEQ ID NO. 1-10 is respectively connected with SEQ ID NO.12 and SEQ ID NO.14 at the same time to obtain a recombinant fragment, and the obtained recombinant fragment is connected to pHT01 plasmid in a Gibson assembly mode to construct recombinant plasmid containing different promoter expression fusion proteins AGAT-GFP. The constructed plasmids are respectively transformed into Bacillus subtilis168, and the Bacillus subtilis is coated on a plate at 37 ℃ until a single colony grows out. Single colonies were picked and cultured in 96-well plates and fluorescence was detected. According to the fluorescent eggThe relative expression level of white represents the relative expression intensity of AGAT, and the fluorescence values (fluorescence/OD) of the ten promoters were 300, 453, 497, 550, 580, 670, 742, 899, 1030, 1245. With the promoter P xpac For control, the relative expression intensity of AGAT was 1,1.51,1.65,1.83, 1.93,2.23,2.47,2.99,3.43,4.15 (table 2).
Example 4 Effect of promoters of different strengths on the production of GAA in engineered bacteria
A single colony of the recombinant strain of example 2 was first picked up and cultured in 3mL of seed culture medium at 37 ℃ and 220rpm for 10 hours. Then, 2.5mL of the seed solution was transferred to 50mL of fermentation medium, and the corresponding antibiotic was added to the medium at 37 ℃ and 220rpm for 15-20 hours, and after cell pellet was collected by centrifugation at 4000rpm for 10min, the pellet was washed with PBS buffer and resuspended in 3mL, and simultaneously substrate was added for whole cell transformation.
Under the condition of whole cell transformation for 48h and other conditions being the same, the GAA yield in the final reaction solution of the sample of the promoter SEQ ID NO.3 is about 1.89g/L; while the higher strength promoter SEQ ID NO.10 sample yielded about 9.53g/L of GAA in the final reaction solution, which was 5.04 times that of the promoter SEQ ID NO.3 sample.
TABLE 2 Effect of promoters with different expression intensities inserted before the coding sequence of key genes on GAA production
Example 5 construction of argI and gcvP knockout strains
P in the selected example 4 566 The recombinant bacillus subtilis is used as a promoter, the deletion of argI (GeneID: 937760) and gcvP (GeneID: 938549) on a bacillus subtilis genome is realized in a fusion PCR mode, the deletion methods of the two genes are the same, and different resistance genes are selected as screening markers. The fusion PCR knock-out frame comprises three partsRespectively carrying out PCR amplification on each fragment at the upstream of a knockout site of the bacillus subtilis genome, the downstream of a resistance gene knockout site to obtain a target fragment, and then carrying out one-round and two-round fusion PCR connection. The integration frame can be directly transformed into a bacillus subtilis competence, the target gene is knocked out through a homologous recombination system, the resistance gene is used as a screening label, a transformant is coated on a resistance plate, a single colony is selected for colony PCR verification, and the recombinant bacillus subtilis with gcvP knocked out on a genome respectively and the recombinant bacillus subtilis with gcvP knocked out and argI knocked out simultaneously are constructed.
Example 6 Effect of Bacillus subtilis genome knockout of argI and gcvP on the production of guanidinoacetic acid by recombinant strains
The recombinant strain with the genomic deletion of gcvP obtained in example 5 was transformed into whole cells, and the concentration of the product was measured after fermentation for 48 hours, which indicated that the yield of guanidinoacetic acid was 10.2g/L. The recombinant strain obtained in example 4, in which gcvP and argI were simultaneously knocked out on the genome, was transformed into whole cells, and the concentration of the product was measured after fermentation for 48 hours, showing that the final yield of guanidinoacetic acid was 12.8g/L. 109.4mM GAA was obtained from 266.7mM glycine and 114.8mM arginine, with GAA conversions of arginine and glycine of 95.3mol% and 41mol%, respectively.
Substrate conversion = moles of substrate actually participating in the reaction/total moles of substrate × 100%.
Comparative example 1
Replacing SEQ ID NO.12 in example 1 with a sequence shown in SEQ ID NO.13, constructing a recombinant plasmid in the manner of example 1, transferring the recombinant plasmid into Bacillus subtilis168 to construct a recombinant bacterium, performing whole-cell transformation in the manner of example 4, and determining GAA in the reaction solution, wherein the result shows that GAA is not detected.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
SEQUENCE LISTING
<110> university of south of the Yangtze river
<120> recombinant bacillus subtilis for producing glycocyamine and construction method thereof
<130> BAA210928A
<160> 14
<170> PatentIn version 3.3
<210> 1
<211> 130
<212> DNA
<213> Artificial sequence
<400> 1
gaatcgtcga cctgtcatag acctgaaaag gtcttttttt gtactcttaa taataaaaag 60
aagatgaaac ttgtttaagg attgaacgta gtagataata atattaaaac tgagaaagga 120
ggtgataaaa 130
<210> 2
<211> 130
<212> DNA
<213> Artificial sequence
<400> 2
gaatcgtcga cctgattatt cttaactttt acgaaacttt gatataataa caaacgtata 60
tattagtaat ttacggctta ttttccttgt gagcgtaaaa ataaatgtga ctataaagga 120
ggtgataaaa 130
<210> 3
<211> 135
<212> DNA
<213> Artificial sequence
<400> 3
gaatcgtcga cctgaaacaa tgaaactttt ttttataaaa aacgactatt ttaggatttc 60
attcttgtat taaatagagt tgtatttatt ggaaatttaa ctcataatga aagtaattta 120
aaggaggtga taaaa 135
<210> 4
<211> 123
<212> DNA
<213> Artificial sequence
<400> 4
gaatcgtcga cctgttttct tgacgccctt ttgagggagg agtaaaatga aattgtcaat 60
aaatcttaat aaagtgctta caattgaaag aagtggggga agagattaaa ggaggtgata 120
aaa 123
<210> 5
<211> 311
<212> DNA
<213> Artificial sequence
<400> 5
gaatcgtcga ctgataggtg gtatgttttc gcttgaactt ttaaatacag ccattgaaca 60
tacggttgat ttaataactg acaaacatca ccctcttgct aaagcggcca aggacgccgc 120
cgccggggct gtttgcgttc ttgccgtgat ttcgtgtacc attggtttac ttattttttt 180
gccaaggctg taatggctga aaattcttac atttatttta catttttaga aatgggcgtg 240
aaaaaaagcg cgcgattatg taaaatataa agtgatagcg gtaccattat aggtaagaga 300
ggaatgtaca c 311
<210> 6
<211> 130
<212> DNA
<213> Artificial sequence
<400> 6
gaatcgtcga cctgttttcg aatgattaaa ttttttgttt tttataaagg ttttttacta 60
ttttgtgaac aatcaaggta gaatcaaatt gcaaacagtg gtaaaatatc gttgaaagga 120
ggtgataaaa 130
<210> 7
<211> 111
<212> DNA
<213> Artificial sequence
<400> 7
gaatcgtcga cctgttgagg aatcatagaa ttttgactta aaaatttcag ttgcttaatc 60
ctacaattct tgatataata ttctcatagt ttgaaaaagg aggtgataaa a 111
<210> 8
<211> 127
<212> DNA
<213> Artificial sequence
<400> 8
gaatcgtcga cctgaaacaa aattcgacaa agttcactga attttcacaa aagatttatg 60
tttcagcagg aattgtaaag ggtaaaagag aaatagatac atatccttaa taaaggaggt 120
gataaaa 127
<210> 9
<211> 130
<212> DNA
<213> Artificial sequence
<400> 9
gaatcgtcga cctgattttg tcaaaataat tttattgaca acgtcttatt aacgttgata 60
taatttaaat tttatttgac aaaaatgggc tcgtgttgta caataaatgt agtgaaagga 120
ggtgataaaa 130
<210> 10
<211> 87
<212> DNA
<213> Artificial sequence
<400> 10
gaatcgtcga caaaaaacgg cctctcgaaa tagagggttg acactctttt gagaatatgt 60
tatattatca gaaaggaggt gataaaa 87
<210> 11
<211> 376
<212> PRT
<213> Artificial sequence
<400> 11
Met Arg Thr Asp Thr Arg Ile Val Asn Ser Trp Asn Glu Trp Asp Thr
1 5 10 15
Leu Gln Glu Val Val Val Gly Thr Ala Glu Asn Ala Cys Phe Glu Pro
20 25 30
Thr Glu Pro Gly His Arg Pro Gln Glu Arg Gly Leu Pro Glu Pro Arg
35 40 45
Pro Phe Pro Thr Gly Pro Lys Pro Arg Glu Leu Asn Glu Lys Ala Glu
50 55 60
Glu Glu Leu Ala Gly Leu Val Ser Leu Leu Glu Thr His Gly Val Thr
65 70 75 80
Val Arg Arg Pro Ser Pro Arg Asp Tyr Ser Ile Pro Leu Lys Thr Pro
85 90 95
Thr Phe Glu Val Glu Asn Gln Tyr Cys Ala Val Cys Pro Arg Asp Val
100 105 110
Met Ile Thr Leu Gly His Glu Ile Leu Glu Ala Thr Met Ser Arg Arg
115 120 125
Ser Arg Tyr Phe Glu Tyr Glu Ala Tyr Arg Ser Leu Val Tyr Glu Tyr
130 135 140
Trp Asp Gln Asp Pro Gln Met Thr Trp Ser Val Ala Pro Lys Pro Ser
145 150 155 160
Met Ala Asp Glu Met Tyr Arg Gln Asp Phe Trp Thr Trp Pro Leu Ser
165 170 175
Lys Arg His Glu Glu Met His Asn Phe Glu Phe Cys Val Thr Gln Asp
180 185 190
Glu Val Val Phe Asp Ala Ala Asp Met Ala Arg Met Gly Lys Asp Ile
195 200 205
Phe Val Gln Glu Ser Met Thr Thr Asn Arg Ala Gly Ile Arg Trp Leu
210 215 220
Thr Arg His Leu Glu Pro Lys Gly Phe Arg Val His Pro Val His Phe
225 230 235 240
Pro Leu Asp Tyr Phe Pro Ser His Ile Asp Ala Thr Phe Ile Pro Leu
245 250 255
Arg Ala Gly Leu Val Leu Thr Asn Pro Glu Arg Pro Ile Ser Ser Gly
260 265 270
Glu Glu Lys Leu Phe Leu Ala Asn Asp Trp Glu Phe Val Thr Ala Pro
275 280 285
Gln Pro Leu Thr Gly Asn Asp Glu Met Pro Arg Tyr Cys Gln Ser Ser
290 295 300
Lys Trp Val Ser Ile Asn Val Leu Ser Ile Ser Pro Ser Lys Ile Ile
305 310 315 320
Val Glu Glu Gln Glu Lys Pro Leu Gln Asp Leu Leu Cys Ser Leu Gly
325 330 335
Phe Glu Val Leu Pro Leu Pro Phe Arg His Val Tyr Glu Tyr Gly Gly
340 345 350
Ser Leu His Cys Ala Thr Trp Asp Val Arg Arg Asp Gly Gly Cys Glu
355 360 365
Asp Tyr Phe Pro Asn Gln Asn Val
370 375
<210> 12
<211> 1131
<212> DNA
<213> Artificial sequence
<400> 12
atgagaacag atacaagaat tgttaattca tggaatgaat gggatacact gcaagaggtt 60
gttgtgggca cagcagaaaa tgcatgcttt gaaccgacag aaccgggcca tagaccgcaa 120
gaaagaggcc tgccggaacc gagaccgttt ccgacgggcc cgaaaccgag agaactgaat 180
gaaaaagcag aagaggaact ggcgggcctg gtttcactgc tggaaacaca tggcgttaca 240
gttagaagac cgtcaccgag agattattca attccgctga aaacaccgac atttgaagtt 300
gaaaatcaat attgcgcagt ttgcccgaga gatgttatga ttacactggg ccatgaaatt 360
ctggaagcaa caatgtcaag aagatcaaga tattttgaat atgaagcata tagatcactg 420
gtttatgaat attgggatca agatccgcaa atgacatggt cagttgcacc gaaaccgtca 480
atggcagatg aaatgtatag acaagatttt tggacatggc cgctgtcaaa aagacatgaa 540
gaaatgcata attttgaatt ttgcgttaca caagatgaag ttgtttttga tgcagcagat 600
atggcaagaa tgggcaaaga tatttttgtt caagaatcaa tgacaacaaa tagagcgggc 660
attagatggc tgacaagaca tctggaaccg aaaggcttta gagttcatcc ggttcatttt 720
ccgctggatt atttcccgtc acatattgat gcaacattta ttccgctgag agcgggcctg 780
gttctgacaa atccggaaag accgatttca agcggcgaag aaaaactgtt tctggcaaat 840
gattgggaat ttgttacagc accgcaaccg ctgacgggca atgatgaaat gccgagatat 900
tgccaatcat caaaatgggt ttcaattaat gttctgtcaa tttcaccgtc aaaaattatt 960
gttgaggagc aagaaaaacc gctgcaagat ctgctgtgct cactgggctt tgaagttctg 1020
ccgctgccgt ttagacatgt ttatgaatac ggcggctcac tgcattgcgc aacatgggat 1080
gttagaagag atggcggctg cgaagattat tttccgaatc aaaatgttta a 1131
<210> 13
<211> 318
<212> DNA
<213> Artificial sequence
<400> 13
atgattctgt atgatacata tccgctgtca gaagaaacat ggcatacaca tcaatttaca 60
tttattaaag atcatgcatt tagactgctg caaccgggcg gcgttctgac atattgcaat 120
ctgacatcat ggggcgaact gctgaaaaca aaatcagata ttgaaaaaat gtttgaagaa 180
acacaaattg gccatctggt tgaagcgggc tttaaaaaag aaaatattag aacaacagtt 240
atggatctgg ttccgccgca agattgcaga tattattcat ttcataaaat gattacaccg 300
acaattatta aacattaa 318
<210> 14
<211> 711
<212> DNA
<213> Artificial sequence
<400> 14
agtaaaggag aagaactttt cactggagtt gtcccaattc ttgttgaatt agatggtgat 60
gttaatgggc acaaattttc tgtcagtgga gagggtgaag gtgatgcaac atacggaaaa 120
cttaccctta aatttatttg cactactgga aagcttcctg ttccttggcc aacacttgtc 180
actactctta cttatggtgt tcaatgcttt tcaagatacc cagatcatat gaagcggcac 240
gacttcttca agagcgccat gcctgaggga tacgtgcagg agaggaccat cttcttcaag 300
gacgacggga actacaagac acgtgctgaa gtcaagtttg agggagacac cctcgtcaac 360
agaatcgagc ttaagggaat cgatttcaag gaggacggaa acatcctcgg ccacaagttg 420
gaatacaact acaactccca caacgtatac atcatggcag acaaacaaaa gaatggaatc 480
aaagttaact tcaaaattag acacaacatt gaagatggaa gcgttcaact agcagaccat 540
tatcaacaaa atactccaat tggcgatggc cctgtccttt taccagacaa ccattacctg 600
tccacacaat ctgccctttc gaaagatccc aacgaaaaga gagaccacat ggtccttctt 660
gagtttgtaa cagctgctgg gattacacat ggcatggatg aactatacaa a 711
Claims (9)
1. Recombinant Bacillus subtilis characterized by expressionAmycolatopsis kentuckyensisThe derived glycin amidine transferase AGAT is knocked outgcvPAnd/orargIA gene; the nucleotide sequence of the gene for coding the glycinamidine transferase AGAT is shown in SEQ ID NO. 12.
2. The recombinant bacillus subtilis of claim 1 wherein the glycine amidinyltransferase AGAT is expressed using promoters of different strengths; the promoter with different strength is P xpac 、P ycec 、P lytR 、P sdhB 、P 43 、P odhA 、P 333 、P yvyD 、P veg Or P 566 (ii) a The P is xpac 、P ycec 、P lytR 、P sdhB 、P 43 、P odhA 、P 333 、P yvyD 、P veg Or P 566 The nucleotide sequences of (A) are respectively shown in SEQ ID NO. 1-10.
3. The recombinant Bacillus subtilis of claim 1 or 2, wherein the recombinant Bacillus subtilis is a Bacillus subtilis straingcvPGene ID of 938549; the above-mentionedargIThe Gene ID was 937760.
4. The recombinant Bacillus subtilis of claim 3 wherein the pHT01 plasmid is the expression vector.
5. A method for producing glycocyamine, characterized in that the recombinant Bacillus subtilis of any one of claims 1 to 4 is used as a fermentation strain, glycine and arginine are used as substrates, and the glycocyamine is produced by fermentation.
6. The method as claimed in claim 5, wherein the concentration of the glycine and the arginine in the reaction system is the same and is 15 to 25 g/L; the recombinant Bacillus subtilisOD of Bacillus in reaction System 600 The ratio is 55 to 65.
7. The method of claim 5, wherein the reaction system comprises 35 to 45g/L of glucose, 10 to 15g/L of yeast powder, 5 to 10g/L of tryptone, 5 to 10g/L of ammonium sulfate, 10 to 15g/L of dipotassium hydrogen phosphate trihydrate, 2 to 5g/L of potassium dihydrogen phosphate, 1 to 5g/L of magnesium chloride and 5 to 10g/L of urea.
8. The method of claim 5~7 wherein the reaction is carried out at 25 to 40 ℃ for 24 to 48 hours.
9. Use of the bacillus subtilis of any one of claims 1~4 in the production of guanidinoacetic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110867868.1A CN113481139B (en) | 2021-07-29 | 2021-07-29 | Recombinant bacillus subtilis for producing glycocyamine and construction method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110867868.1A CN113481139B (en) | 2021-07-29 | 2021-07-29 | Recombinant bacillus subtilis for producing glycocyamine and construction method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113481139A CN113481139A (en) | 2021-10-08 |
| CN113481139B true CN113481139B (en) | 2022-11-08 |
Family
ID=77944637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110867868.1A Active CN113481139B (en) | 2021-07-29 | 2021-07-29 | Recombinant bacillus subtilis for producing glycocyamine and construction method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113481139B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023232583A1 (en) | 2022-06-03 | 2023-12-07 | Evonik Operations Gmbh | Improved biotechnological method for producing guanidino acetic acid (gaa) by using nadh-dependent dehydrogenases |
| WO2024094483A1 (en) * | 2022-11-03 | 2024-05-10 | Evonik Operations Gmbh | Improved biotechnological process to produce guanidinoacetic acid (gaa) by targeted introduction or by increasing the activity of a transmembrane transport protein belonging to the amino acid-polyamine-organocation superfamily |
| WO2024094481A1 (en) * | 2022-11-03 | 2024-05-10 | Evonik Operations Gmbh | Improved biotechnological process to produce guanidinoacetic acid (gaa) by targeted introduction or by increasing the activity of a transmembrane exporter protein |
| WO2024165348A1 (en) | 2023-02-06 | 2024-08-15 | Evonik Operations Gmbh | Process for preparing an n-guanylamino acid |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111748506A (en) * | 2019-03-29 | 2020-10-09 | 中国科学院微生物研究所 | Engineering bacterium for producing glycocyamine and construction method and application thereof |
| WO2021122400A1 (en) * | 2019-12-19 | 2021-06-24 | Evonik Operations Gmbh | Method for the fermentative production of guanidinoacetic acid |
-
2021
- 2021-07-29 CN CN202110867868.1A patent/CN113481139B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111748506A (en) * | 2019-03-29 | 2020-10-09 | 中国科学院微生物研究所 | Engineering bacterium for producing glycocyamine and construction method and application thereof |
| WO2021122400A1 (en) * | 2019-12-19 | 2021-06-24 | Evonik Operations Gmbh | Method for the fermentative production of guanidinoacetic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113481139A (en) | 2021-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113481139B (en) | Recombinant bacillus subtilis for producing glycocyamine and construction method thereof | |
| CN108103120B (en) | Method for synthesizing L-aspartic acid by catalyzing maleic acid through double-enzyme coupled whole cells | |
| CN106047913B (en) | Construction method of double-enzyme co-expression strain for producing alpha-ketoglutaric acid | |
| CN112877270B (en) | Genetic engineering bacterium for producing hydroxyl tetrahydropyrimidine and application thereof | |
| CN109777763A (en) | One plant for the genetic engineering bacterium of L-thiamine production and its building and application | |
| CN102041241A (en) | High-efficiency ammonium-excreting combined azotobacter strain | |
| CN107201374B (en) | Construction method and application of optical pure meso-2, 3-butanediol high-yield engineering strain | |
| CN112961815B (en) | Genetic engineering bacterium for high yield of tetrahydropyrimidine and application thereof | |
| WO2024099089A1 (en) | Genetically engineered strain for producing pseudouridine, construction method therefor and use thereof | |
| CN112481178B (en) | Construction of amino bisdemethoxycurcumin high-yield strain and fermentation optimization method thereof | |
| CN107287144B (en) | Metabolically-modified bacillus subtilis biotransformation cell and preparation method and application thereof | |
| CN113549633A (en) | L-cysteine transporter mutant and application thereof in production of L-cysteine | |
| CN109913515B (en) | Method for increasing yield of poly gamma-glutamic acid by improving glycerol metabolism of bacillus | |
| CN113073074A (en) | Genetically engineered bacterium for efficiently synthesizing riboflavin and application thereof | |
| CN108588108B (en) | Preparation method and application of bacillus for efficiently metabolizing glycerol | |
| CN111607608A (en) | Gene engineering high-yield strain streptomyces diastatochromogenes, method for improving yield of polylysine and application | |
| CN110305917B (en) | Application of rex gene of bacillus in improving yield of poly-gamma-glutamic acid | |
| CN108165516B (en) | Method for producing leucine dehydrogenase by fermenting bacillus subtilis | |
| CN110872595B (en) | Acid-resistant expression cassette and application thereof in fermentation production of organic acid | |
| CN112852847A (en) | Recombinant saccharomyces cerevisiae strain and construction method and application thereof | |
| CN116814514B (en) | Method for improving fermentation yield of escherichia coli L-lysine | |
| CN101892228B (en) | Engineering bacteria with high tolerance to acrylamide and acrylonitrile for producing nitrile hydratase and application thereof | |
| CN114806996B (en) | High-yield pentanediamine genetically engineered bacterium, construction method and application | |
| CN115011537B (en) | Engineering bacterium for producing high optical purity L-lactic acid by double anaerobic promoters and preparation method and application thereof | |
| CN115125180B (en) | Recombinant zymomonas mobilis for producing acetoin by double ways and construction method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |